Xenograft Model Antitumor Assays
"Xenograft Model Antitumor Assays" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
| Descriptor ID |
D023041
|
| MeSH Number(s) |
E05.337.550.200.900 E05.624.850
|
| Concept/Terms |
Xenograft Model Antitumor Assays- Xenograft Model Antitumor Assays
- Tumor Xenograft Assay
- Xenograft Antitumor Assays
- Antitumor Assay, Xenograft
- Antitumor Assays, Xenograft
- Assay, Xenograft Antitumor
- Assays, Xenograft Antitumor
- Xenograft Antitumor Assay
- Antitumor Assays, Xenograft Model
|
Below are MeSH descriptors whose meaning is more general than "Xenograft Model Antitumor Assays".
Below are MeSH descriptors whose meaning is more specific than "Xenograft Model Antitumor Assays".
This graph shows the total number of publications written about "Xenograft Model Antitumor Assays" by people in this website by year, and whether "Xenograft Model Antitumor Assays" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 6 | 6 |
| 2003 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 3 | 4 |
| 2007 | 0 | 5 | 5 |
| 2008 | 0 | 7 | 7 |
| 2009 | 2 | 10 | 12 |
| 2010 | 3 | 11 | 14 |
| 2011 | 1 | 18 | 19 |
| 2012 | 2 | 15 | 17 |
| 2013 | 3 | 20 | 23 |
| 2014 | 0 | 29 | 29 |
| 2015 | 0 | 29 | 29 |
| 2016 | 0 | 42 | 42 |
| 2017 | 2 | 38 | 40 |
| 2018 | 3 | 29 | 32 |
| 2019 | 2 | 39 | 41 |
| 2020 | 1 | 38 | 39 |
| 2021 | 5 | 28 | 33 |
| 2022 | 0 | 7 | 7 |
| 2023 | 0 | 3 | 3 |
| 2024 | 2 | 19 | 21 |
| 2025 | 0 | 32 | 32 |
| 2026 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.
-
MiR-200c restoration inhibits FOXP3 and metastatic spread in breast cancer: evidence from in vitro and in vivo models. BMC Cancer. 2026 Feb 14; 26(1).
-
Ubiquitination of Oncogenic Mutant p53 via Attenuation of Ribosome Biogenesis Machinery Effectively Inhibits Pancreatic Tumor Growth. Mol Cancer Ther. 2026 Feb 04; 25(2):257-271.
-
Discovery and Characterization of a First-In-Class HCK/BTK PROTAC DFCI-002-06 for the Treatment of MYD88 Mutated B Cell Malignancies. J Med Chem. 2026 Jan 22; 69(2):1119-1134.
-
Dual targeting of AMRC12 and Malassezia globosa disrupts MYC liquid condensates-driven nuclear pore complex biogenesis in neuroblastoma. Theranostics. 2026; 16(6):2866-2886.
-
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML. Leukemia. 2026 Feb; 40(2):304-313.
-
Dinaciclib improves treatment response in chemoresistant hepatoblastoma. Sci Rep. 2025 Dec 05; 16(1):1410.
-
Targeting TET3 suppresses group 3 medulloblastoma stemness and progression via impairing hypomethylation of Otx2 super-enhancer. Cell Rep Med. 2025 Dec 16; 6(12):102474.
-
Targeting FZD6 creates therapeutically actionable vulnerabilities for advanced prostate cancer. Oncogene. 2025 Dec; 44(50):4868-4877.
-
An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Na?ve and Longitudinal Samples during Neoadjuvant Chemotherapy. Cancer Res. 2025 Nov 03; 85(21):4062-4080.
-
Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b. Cancer Immunol Res. 2025 Nov 03; 13(11):1732-1748.